Pathfinder, LLC and SyntheMed, Inc. (SYMD.OB) Complete Merger
9/6/2011 11:18:51 AM
More...
|
Pathfinder Therapeutics Cells Demonstrate Ability to Regenerate Damaged Tissue and Restore Pancreatic Function in a Diabetic Mouse Model
3/29/2011 7:02:14 AM
More...
|
Pathfinder LLC and SyntheMed, Inc. (SYMD.OB) Announce Merger Agreement
12/27/2010 9:11:52 AM
More...
|
SyntheMed, Inc. (SYMD.OB) Receives CE Mark Approval for REPEL-GYN(TM)
5/24/2010 8:16:17 AM
More...
|
SyntheMed, Inc. (SYMD.OB) Completes $1.0 Million Equity Placement
10/1/2009 11:03:26 AM
More...
|
SyntheMed, Inc. (SYMD.OB) Receives Brazilian Regulatory Approval for REPEL-CV(TM)
9/9/2009 9:00:49 AM
More...
|
SyntheMed, Inc. (SYMD.OB) Receives Russian Regulatory Approval for REPEL-CV(TM)
8/19/2009 12:00:47 PM
More...
|
SyntheMed, Inc. (SYMD.OB) Receives Australian Regulatory Approval for REPEL-CV(R)
5/28/2009 10:17:18 AM
More...
|
FDA Approves SyntheMed, Inc. (SYMD.OB)'s REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
3/9/2009 8:11:10 AM
More...
|
SyntheMed, Inc. (SYMD.OB) Announces FDA Clearance of SinusShield(TM)
11/20/2008 6:43:25 AM
More...
|
|